---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Thyroid hormone receptor-beta agonists"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Thyroid hormone receptor-beta agonists. Topics: FDA-approved indication and dosage: resmetirom; MAESTRO-NASH week 52 primary end points: 966-patient primary analysis population; EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis; EASL-EASD-EASO guideline: response rates, duration of therapy, and use with GLP-1 receptor agonists; 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/thyroid-hormone-receptor-beta-agonists"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Thyroid hormone receptor-beta agonists

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Thyroid Hormone Receptor-beta Agonists

<a id="topic-2.2.2.1.2-1"></a>

### FDA-approved indication and dosage: resmetirom

> “REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).”
> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis”
> “Avoid use of REZDIFFRA in patients with decompensated cirrhosis”
> “The recommended dosage of REZDIFFRA is based on actual body weight.”
> “<100 kg, the recommended dosage is 80 mg orally once daily.”
> “≥100 kg, the recommended dosage is 100 mg orally once daily.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### MAESTRO-NASH week 52 primary end points: 966-patient primary analysis population

> “We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3”
> “Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group).”
> “NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Diarrhea and nausea were more frequent with resmetirom than with placebo.”

Source: [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000)

<a id="topic-2.2.2.1.2-3"></a>

### EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis

> “If approved locally and dependent on the label, adults with non-cirrhotic MASH with significant liver fibrosis (stage ≥2) should be considered for treatment with resmetirom as a MASH-targeted therapy, as this treatment demonstrated histological efficacy on steatohepatitis and fibrosis in a large phase III registrational trial with an acceptable safety and tolerability profile (LoE 2, strong recommendation, consensus).”
> “Treatment with resmetirom, if approved locally, may be considered for individuals with MASLD who are non-cirrhotic and with documentation of either: (A) advanced fibrosis; (B) at-risk steatohepatitis with significant fibrosis (by liver biopsy, when available, or by non-invasive panels validated for that purpose); or (C) risk of adverse liver-related outcomes (e.g. by elastography- or biomarker-defined thresholds) (LoE 3, open recommendation, consensus).”
> “No MASH-targeted pharmacotherapy can currently be recommended for adults with MASH at the cirrhotic stage (LoE 5, weak recommendation, strong consensus).”
> “For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (LoE 5, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

### EASL-EASD-EASO guideline: response rates, duration of therapy, and use with GLP-1 receptor agonists

> “Similarly, there is currently no evidence to provide confident guidance on when to stop treatment, particularly considering that about 70-80 % of participants did not respond to treatment according to histological criteria.”
> “Therefore, it appears reasonable to use resmetirom according to the same criteria in individuals already receiving GLP1RA treatment.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.2-5"></a>

### AASLD update to the practice guidance: resmetirom patient selection and exclusions

> “This article serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease”
> “Resmetirom can be considered for treatment of adults with MASH and moderate to advanced liver fibrosis (consistent with F2-F3).”
> “Noninvasive liver disease assessment—preferably imaging-based test results—consistent with MASH with F2-F3, or”
> “Historical liver biopsy demonstrating MASH with F2-F3 (and without evidence of concomitant, histologically active autoimmune liver disease).”
> “Resmetirom is not recommended for persons with compensated or decompensated cirrhosis, concomitant uncontrolled active liver diseases (such as autoimmune hepatitis and primary biliary cholangitis), or ongoing alcohol consumption greater than 20 g/d for women or greater than 30 g/d for men.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-6"></a>

### AASLD update to the practice guidance: continuation or discontinuation of resmetirom at 12 months

> “The decision to continue treatment beyond 12 months should be based on assessing whether a patient has evidence of improvement, worsening or treatment failure, or disease stabilization.”
> “Continuation of resmetirom treatment in persons with significant fibrosis improvement is recommended.”
> “Among persons with evidence of worsening liver disease at 12 months of treatment, discontinuation of resmetirom should be considered.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-7"></a>

### AASLD update to the practice guidance: resmetirom in persons already receiving other therapies with potential MASH benefit

> “The MAESTRO-NASH trial notably excluded individuals who initiated or dose-modified drugs with GLP-1 receptor agonist activity, thiazolidinediones, or vitamin E within 6 months of randomization”
> “Among persons already taking any of these medications with potential efficacy for treating MASH, data are insufficient to guide prescribers about whether or when to initiate resmetirom therapy.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-8"></a>

### ADA Standards of Care recommendation 4.28: referral for thyroid hormone receptor-β agonist treatment in adults with type 2 diabetes or prediabetes

> “For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management. A”
> “Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
